Alzheon to Present Clinical Data at 11th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
FRAMINGHAM, Mass., October 24, 2018 – Alzheon, Inc., (Alzheon) a clinical stage biopharmaceutical company with a late-stage program in Alzheimer’s disease (AD) and a discovery platform of small molecules for the inhibition of protein misfolding, today announced that it will be presenting clinical data at the 11th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference to be held on October 24-27 in Barcelona, Spain.
At the CTAD conference, Alzheon will be presenting clinical data on the advancement of ALZ‑801 to to treat AD. Three poster presentations at CTAD will highlight Alzheon’s new scientific advances and its clinical drug candidate, ALZ-801, an orally-administered, anti-amyloid inhibitor designed to block the formation of toxic amyloid oligomers associated with the development and progression of AD.
The details for the presentations at CTAD, which will be presented for the duration of meeting from October 24-27, are as follows and include two late-breaking poster presentations:
Poster Presentation #P141
Title: Clinical Effects of Oral Tramiprosate in APOE4/4 Homozygotes with Mild Alzheimer’s Disease (AD): Responder Analyses of Cognitive and Functional Outcomes
Authors: Susan Abushakra, MD, Chief Medical Officer, Alzheon, Inc; Bruno Vellas, MD, University of Toulouse; Serge Gauthier, MD, McGill University, Montreal, Canada; et al.
Poster Presentation #LBP25 (Late Breaker)
Title: APOE4/4 Early to Mild AD Subjects Show High Rates of Hippocampal Atrophy and Cognitive Decline in ADNI-1 and Tramiprosate Datasets
Authors: Susan Abushakra, MD, Chief Medical Officer, Alzheon, Inc.; Luc Bracoud, BioClinica, Lyon, France; Joel Schaerer, BioClinica, Lyon, France; et al.
Poster Presentation #LBP27 (Late Breaker)
Title: Discovery of an Endogenous Metabolite of Tramiprosate and its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in Human Brain
Authors: John A. Hey, PhD, Chief Scientific Officer, Alzheon, Inc.; Petr Kocis, PhD, Alzheon, Inc.; Jakub Hort, MD, PhD, Director of the Memory Disorders Clinic at Motol University Hospital and Associate Professor of Medicine at Charles University, Prague, Czech Republic; et al.
“We look forward to this Alzheimer’s clinical forum where we can share our scientific discoveries and precision medicine approach to Alzheimer’s with colleagues around the world,” said Martin Tolar, MD, PhD, Founder, President and CEO of Alzheon.
Alzheon’s lead product candidate, ALZ-801, is a patented, orally administered prodrug of tramiprosate that is designed to inhibit beta amyloid oligomer formation. ALZ-801 was granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of AD in October 2017. In clinical trials for ALZ-801’s active ingredient, tramiprosate, a similar adverse event profile was observed across treatment groups and placebo, and in Alzheon’s post hoc analyses of data from these trials, promising clinical signals in a subset of patients with two copies of the APOE4 gene (APOE4/4 homozygotes) were observed. ALZ-801 acts through a novel molecular mechanism of action by blocking the formation of toxic amyloid oligomers considered key drivers of the pathogenesis of AD. Alzheon is currently conducting a Phase 1b trial of ALZ-801 in APOE4 patients with early to mild AD, and plans to commence a Phase 2b trial of ALZ-801 in APOE4/4 homozygotes patients with early to mild AD in the United States and, possibly, internationally in the first half of 2019.
Alzheon, Inc. is a clinical stage biopharmaceutical company with a late-stage program in Alzheimer’s disease and a discovery platform of small molecules for the inhibition of protein misfolding and aggregation in neurodegenerative disorders. Alzheon’s lead product candidate, ALZ-801, is an orally administered inhibitor of beta amyloid misfolding and is a patented prodrug of tramiprosate, which has been evaluated in clinical trials involving over 2,000 patients. Alzheon is focused on developing disease modifying treatments and applying a precision medicine approach for patients with Alzheimer’s and other neurological disorders by leveraging its expertise in inhibiting protein misfolding and aggregation.
The Yates Network